Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 12:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Irritable Bowel Syndrome-Constipation Clear all
Completed Phase 2 Interventional Results available

A Single-Dose, Open-Label, Study to Evaluate the Sustainability of the Effects of SYN-010 in Patients With IBS-C

NCT02493036
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation (IBS-C)
Interventions
SYN-010
Drug
Lead sponsor
Theriva Biologics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
11
States / cities
Hialeah, Florida • Miami, Florida • Miami Lakes, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2018 · Synced Jul 24, 2026, 12:52 AM EDT
Completed Phase 3 Interventional Results available

Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C)

NCT02493452
View directory record Official record
Conditions
Irritable Bowel Syndrome Characterized by Constipation
Interventions
Plecanatide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
191
States / cities
Birmingham, Alabama • Guntersville, Alabama • Huntsville, Alabama + 157 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Jul 24, 2026, 12:52 AM EDT
Recruiting No phase listed Observational

Indiana University Gastrointestinal Motility Diagnosis Registry

NCT04506593
View directory record Official record
Conditions
Eosinophilic Esophagitis, Gastroesophageal Reflux Disease (GERD), Gastroparesis, Functional Vomiting, Irritable Bowel Syndrome (IBS), Constipation, Chronic Intestinal Pseudo-obstruction, Fecal Incontinence, Small Intestinal Bacterial Overgrowth
Interventions
no intervention
Other
Lead sponsor
Indiana University
Other
Eligibility
Not listed
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jul 24, 2026, 12:52 AM EDT
Terminated Phase 2 Interventional

Use of Novel Prebiotic Fiber for Targeted Dietary Management of Irritable Bowel Syndrome (Nutrabiotix Phase II)

NCT02144753
View directory record Official record
Conditions
Constipation-predominant IBS (IBS-C)
Interventions
NTX-1, psyllium (15 g)
Dietary Supplement · Drug
Lead sponsor
Nutrabiotix, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 1, 2016 · Synced Jul 24, 2026, 12:52 AM EDT
Completed Phase 3 Interventional Results available

A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

NCT03573908
View directory record Official record
Conditions
Irritable Bowel Syndrome Characterized by Constipation
Interventions
Linaclotide, Placebo
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
79
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2020 · Synced Jul 24, 2026, 12:52 AM EDT
Recruiting Phase 2 Interventional

A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)

NCT07545772
View directory record Official record
Conditions
Irritable Bowel Syndrome, Constipation
Interventions
LY3537031, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
14
States / cities
Mesa, Arizona • Anaheim, California • Lancaster, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 24, 2026, 12:52 AM EDT
Terminated Phase 2 Interventional Results available

Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)

NCT04043455
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Olorinab, Placebo
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
69
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Jul 24, 2026, 12:52 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Effect of SYN-010 on Subjects With IBS-C

NCT02495623
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation (IBS-C)
Interventions
SYN-010 21 mg, SYN-010 42 mg, Placebo
Drug
Lead sponsor
Theriva Biologics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 26, 2018 · Synced Jul 24, 2026, 12:52 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

AcuGraph and Digestive Symptoms

NCT00846794
View directory record Official record
Conditions
Digestive Disorders, Irritable Bowel Syndrome, Constipation, Diarrhea
Interventions
Not listed
Lead sponsor
Logan College of Chiropractic
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Chesterfield, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Jul 24, 2026, 12:52 AM EDT
Completed Not applicable Interventional Results available

The Effect of CSP01 on Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation

NCT03054506
View directory record Official record
Conditions
Constipation, Chronic Idiopathic Constipation, Irritable Bowel Syndrome With Constipation
Interventions
CSP01, Carboxymethylcellulose (CMC), Placebo
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
22 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Jul 24, 2026, 12:52 AM EDT
Completed Phase 3 Interventional

Treatment of Functional Bowel Disorders

NCT00006157
View directory record Official record
Conditions
Irritable Bowel Syndrome, Constipation, Abdominal Pain, Functional Colonic Diseases
Interventions
Desipramine, Cognitive Behavioral Treatment
Drug · Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2001
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 12, 2010 · Synced Jul 24, 2026, 12:52 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Plecanatide in Children 6 to <18 Years With Irritable Bowel Syndrome With Constipation (IBS-C)

NCT03596905
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation
Interventions
Plecanatide, Matching placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
6 Years to 18 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
35
States / cities
Saraland, Alabama • Scottsdale, Arizona • Corona, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Jul 24, 2026, 12:52 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Curcumin (Tumeric) in the Treatment of Irritable Bowel Syndrome: A Randomized-Controlled Trial

NCT00779493
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
curcumin, placebo
Dietary Supplement
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2015 · Synced Jul 24, 2026, 12:52 AM EDT
Completed Phase 3 Interventional Results available

An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation

NCT00730171
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation, Chronic Constipation
Interventions
Linaclotide
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
116
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 106 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2018 · Synced Jul 24, 2026, 12:52 AM EDT
Not listed Phase 2Phase 3 Interventional

A Study of the Safety and Effectiveness of DDP733 in Treating IBS With Constipation in Females

NCT00547469
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
DDP733
Drug
Lead sponsor
Dynogen Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
62
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 53 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2008 · Synced Jul 24, 2026, 12:52 AM EDT
Withdrawn No phase listed Observational

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in IBS

NCT04214470
View directory record Official record
Conditions
Irritable Bowel, Irritable Bowel Syndrome, Irritable Bowel Syndrome With Diarrhea, Irritable Bowel Syndrome Mixed, Irritable Bowel Syndrome With Constipation, Irritable Bowel Syndrome Without Diarrhea, Irritable Bowel Syndrome Aggravated, Irritable Bowel Syndrome Characterized by Constipation, Irritable Bowel Syndrome Characterised by Alternating Bowel Habit
Interventions
No intervention
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Jul 24, 2026, 12:52 AM EDT
Active, not recruiting Phase 2 Interventional

4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs

NCT06553547
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation (IBS-C)
Interventions
Tenapanor, Placebo
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
6 Years to 11 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
20
States / cities
Little Rock, Arkansas • Hartford, Connecticut • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 24, 2026, 12:52 AM EDT
Completed Phase 3 Interventional Results available

A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C

NCT02727751
View directory record Official record
Conditions
Constipation Predominant Irritable Bowel Syndrome
Interventions
Tenapanor
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 75 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 8, 2020 · Synced Jul 24, 2026, 12:52 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Abdominal Symptom Phenotype Study in Children

NCT01204515
View directory record Official record
Conditions
Irritable Bowel Syndrome (IBS)
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
7 Years to 12 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2013 · Synced Jul 24, 2026, 12:52 AM EDT
Completed Phase 3 Interventional Results available

The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)

NCT02387359
View directory record Official record
Conditions
Irritable Bowel Syndrome Characterized by Constipation
Interventions
Plecanatide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,054 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
155
States / cities
Athens, Alabama • Birmingham, Alabama • Dothan, Alabama + 142 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Jul 24, 2026, 12:52 AM EDT
Completed Phase 3 Interventional Results available

A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C

NCT02621892
View directory record Official record
Conditions
Constipation Predominant Irritable Bowel Syndrome
Interventions
Tenapanor, Placebo
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 75 Years
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
111
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 92 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Jul 24, 2026, 12:52 AM EDT
Completed Not applicable Interventional Results available

Effect of Lubiprostone on Small Bowel Contractions in Female Patients With Constipation Irritable Bowel Syndrome (C-IBS)

NCT01085643
View directory record Official record
Conditions
Constipation-predominant Irritable Bowel Syndrome
Interventions
Lubiprostone, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2011 · Synced Jul 24, 2026, 12:52 AM EDT
Completed Phase 1 Interventional

Lubiprostone Effects on Visceral Pain Sensitivity

NCT01166789
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Lubiprostone, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 15, 2011 · Synced Jul 24, 2026, 12:52 AM EDT
Completed Phase 4 Interventional Results available

Pregabalin on Colonic Motor and Sensory Function in Constipation Predominant Irritable Bowel Syndrome

NCT01331213
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Pregabalin, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 2, 2014 · Synced Jul 24, 2026, 12:52 AM EDT